Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIDA-B
NCT02028949Phase 1Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Nov 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Dose-Limiting Toxicity at 7 weeks. Started Nov 2012; status: completed.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02028949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028949.